| Symbol
| MME
| contributors: mct - updated : 11-10-2016
|
| HGNC name
| membrane metallo-endopeptidase
|
| HGNC id
| 7154
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in acute lymphoblastic leukemias | | constitutional
| germinal mutation
|
|
|
| |
truncating mutations causing alloimmunisation during pregnancy and diopathic renal failure in early adulthood (might be caused by immune-mediated fetal nephron loss) | | constitutional
|
|
|
| gain of function
|
per se mediates insulin secretory dysfunction  | | tumoral
|
|
|
| loss of function
| |
hypoxia negatively regulates the tumor suppressor function of MME in prostate cancer | | tumoral
|
|
| --low
|
| |
in prostate cancer | | constitutional
|
|
|
| loss of function
| |
reduction in MME and IDE activity is not the primary cause of APP accumulation in Alzheimer disease, but rather a late-stage phenomenon secondary to neurodegeneration | |
| Susceptibility
|
to late-onset Alzheimer's disease |
Variant & Polymorphism
| 
| |
| Candidate gene
| for the development of alternative therapies for Alzheimer's disease |
| Marker
| tumoral MME expression correlated with aggressive histologic types and higher mitotic activity and is an independent prognostic factor for patients with malignant pleural mesothelioma |
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| neurology | neurodegenerative | alzheimer | |
| recombinant brain-targeted neprilysin, ASN12, may be an effective treatment for AD and warrant further investigation in clinical trials | | diabete | | | |
| interventions to inhibit neprilysin may improve beta-cell function in obese humans with type 2 diabetes | | cancer | reproductive | prostate | |
| upregulation of MME may provide a novel therapeutic strategy in prostate cancer |
| |
|
| mice deficient in neprilysin showed no obvious degenerative changes in peripheral nerves |